Catheter Related Bloodstream Infection Pipeline Review 2021 Overview
Catheter Related Bloodstream Infection- Pipeline Review
Catheter-related bloodstream infection (CRBSI) is also termed as catheter-related sepsis. It is defined as the existence of bacteraemia originating from an i.v. catheter. It is also the most common cause of nosocomial bacteraemia. It is one of the most common, fatal and costly complications of central venous catheterization. The numbers of CRBSI rising from central venous catheters may exceed 10%. CRBSI has a mortality rate of up to 25% and considerably proliferates hospital length of stay and overall treatment costs.
Table 1. Organisms causing CRBS
CorMedix Inc. is a biopharmaceutical company focused on manufacturing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. Neutrolin is a drug developed by CorMedix. It is a novel, non-antibiotic antimicrobial solution developed for the prevention of catheter-related bloodstream infections (“CRBSIs”) in patients suffering from end-stage renal disease. In Europe and other territories, Neutrolin is already marketed as a CE Marked product. In the U.S., Neutrolin is an investigational drug product with FDA Fast Track status and is labelled as a Qualified Infectious Disease Product (QIDP).
Neutrolin has completed its Phase 3 clinical study, called as LOCK-IT-100. The main objective of the LOCK-IT-100 clinical study was to determine the efficacy and safety of Neutrolin as a catheter lock solution (CLS) for prevention of catheter-related bloodstream infection (CRBSI) in accordance of hemodialysis (HD) for the treatment of End Stage Renal Disease (ESRD) as compared with heparin.
Approximately 70% of pipeline drugs for catheter related bloodstream infection are in phase 3 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Catheter Related Bloodstream Infection.
Report Description
The report on Catheter Related Bloodstream Infection- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Catheter Related Bloodstream Infection. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.
Report Scope
- Assessment of pipeline products based on various stages of devolvement.
- Provides an overview of the global therapeutic landscape of Catheter Related Bloodstream Infection (Infectious Disease).
- Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
- The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
- Latest news, articles, press-release, and related conferences